Contriving multiepitope subunit vaccine by exploiting structural and nonstructural viral proteins to prevent Epstein-Barr virus-associated malignancy
| Autor: | Rupal Ojha, Raj Nandani, Vijay Kumar Prajapati |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Epstein-Barr Virus Infections Herpesvirus 4 Human Physiology Helper T lymphocyte medicine.medical_treatment Clinical Biochemistry Epitopes T-Lymphocyte Immune receptor Biology Viral Nonstructural Proteins medicine.disease_cause Epitope Virus 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases medicine Humans Immunogenicity Viral Vaccines Cell Biology Virology Epstein–Barr virus Molecular Docking Simulation CTL 030104 developmental biology 030220 oncology & carcinogenesis Vaccines Subunit Epitopes B-Lymphocyte Adjuvant Epitope Mapping |
| Zdroj: | Journal of cellular physiology. 234(5) |
| ISSN: | 1097-4652 |
| Popis: | Cancer is one of the common lifestyle diseases and is considered to be the leading cause of death worldwide. Epstein-Barr virus (EBV)-infected individuals remain asymptomatic; but under certain stress conditions, EBV may lead to the development of cancers such as Burkitt's and Hodgkin's lymphoma and nasopharyngeal carcinoma. EBV-associated cancers result in a large number of deaths in Asian and African population, and no effective cure has still been developed. We, therefore, tried to devise a subunit vaccine with the help of immunoinformatic approaches that can be used for the prevention of EBV-associated malignancies. The epitopes were predicted through B-cell, cytotoxic T lymphocytes (CTL), and helper T lymphocytes (HTL) from the different oncogenic proteins of EBV. A vaccine was designed by combining the B-cell and T-cell (HTL and CTL) epitopes through linkers, and for the enhancement of immunogenicity, an adjuvant was added at the N-terminal. Further, homology modeling was performed to generate the 3D structure of the designed vaccine. Moreover, molecular docking was performed between the designed vaccine and immune receptor (TLR-3) to determine the interaction between the final vaccine construct and the immune receptor complex. In addition, molecular dynamics was performed to analyze the stable interactions between the ligand final vaccine model and receptor TLR-3 molecule. Lastly, to check the expression of our vaccine construct, we performed in silico cloning. This study needed experimental validation to ensure its effectiveness and potency to control malignancy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text